Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

age clinical studies," said Mr. Swisher.

Actions taken today will allow the company to direct most of its resources into the late-stage development of voreloxin. Sunesis expects this realignment of personnel and programs to reduce annual operating expenses by more than $15 million, thus enabling increased investment into such development. Current burn rate guidance for the second half of 2008 is in the range of $12-15 million, including payment of severance and other restructuring charges.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication- dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: ... its corporate presentations at two upcoming investor conferences.  ... UK on Tuesday, December 2, 2014 at 6:45 a.m. ... president and head of EUSA International, will provide an overview of ... th Annual Piper Jaffray Healthcare Conference in New ...
(Date:11/24/2014)... Inc. (NYSE: CRY ), a leading medical device ... announced today that it will participate in the upcoming 26 ... 3, 2014 at The New York Palace Hotel in ... webcast of the Company,s presentation is scheduled to begin at ... company by Pat Mackin , President and Chief Executive ...
(Date:11/24/2014)... -- Marta Rendon, MD, founder of the Rendon Center for Dermatology ... international key opinion leader in dermatology, was one of only ... to attend the international Aesthetic Experts Summit held ... at this gathering of over 600 physicians from 57 countries, ... experts from Asia and ...
Breaking Medicine Technology:Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3
... Arriva Medical, a leading national provider of diabetic ... in a transaction valued at approximately $23 million.  The ... closing, and contingent payments which are expected to total ... customer base of approximately 120,000 active customers.  As part ...
... 2012 The Providence Service Corporation (Nasdaq: ... for the fourth quarter and year ended December 31, ... February 15, 2012.Fourth Quarter 2011 ResultsFor the fourth quarter ... an increase of 11.4% from $219.3 million in the ...
Cached Medicine Technology:Providence Service Corporation Reports 2011 Results 2Providence Service Corporation Reports 2011 Results 3Providence Service Corporation Reports 2011 Results 4Providence Service Corporation Reports 2011 Results 5Providence Service Corporation Reports 2011 Results 6Providence Service Corporation Reports 2011 Results 7Providence Service Corporation Reports 2011 Results 8
(Date:11/26/2014)... (PRWEB) November 26, 2014 Louisiana ... relief and specialists in minimally invasive spine surgery, ... Shamieh into the rapidly growing provider network of ... The addition coincides with the network’s continuing success ... treatment for Louisiana residents who are suffering from ...
(Date:11/26/2014)... of the most important and vital decisions a woman ... choosing the ideal wedding dress and bridesmaid dresses. BellasDress.com ... quality outfits. Today, BellasDress.com has unveiled its new range ... suitable bridesmaid gowns here at discount prices. , Formal ... and highlight all their most beautiful features while drawing ...
(Date:11/26/2014)... News) -- Teens prescribed anti-anxiety or sleep medications ... than other teens, a new study warns. ... abuse assessments on teenagers before prescribing these drugs ... parents don,t realize the abuse potential," said lead ... of Michigan School of Nursing. "These drugs produce ...
(Date:11/26/2014)... Steven Reinberg HealthDay Reporter ... rules announced Tuesday by the U.S. Food and Drug Administration ... menus, and the rules even apply to movie theater popcorn ... third of their calories away from home, often consuming less ... Dr. Margaret Hamburg said during a Monday afternoon news conference. ...
(Date:11/24/2014)... Recently, Fecbek.com ( http://www.fecbek.com ), a leading online shopping ... the history of the Black Friday to its fans worldwide. ... It is the Black Friday! It is a shopping day ... China. However, not everyone knows the history of the Special ... special day. , The fourth Friday in November is the ...
Breaking Medicine News(10 mins):Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3
... May 24 (HealthDay News) -- Japanese-American men who don,t eat ... of stroke later in life, according to a new, long-term ... in Hawaii. They were between the ages of 45 ... first examined and interviewed about their eating habits. During ...
... Our cells breathe and digest, as does the organism as ... contained in the nutrients they ingest, before discarding the waste, ... for the cells. Its digestion occurs in the cytoplasm, in ... pyruvate and a small amount of energy. Pyruvate is then ...
... the benefits of a virtual exercise partner shows the presence ... the motivation by as much as 100 percent ... of Michigan State University,s Department of Kinesiology shows women taking ... with a virtual partner, results the authors said can be ...
... Fatigue is a common problem among surgery residents, a small, ... that fatigue may play a major role in medical errors, ... Program and Massachusetts General Hospital in Boston, and colleagues. ... average of 5.3 hours a day, with average individual amounts ...
... 2012) -- A team of scientists at McMaster University ... cells in the human while avoiding the toxic side-effects ... our finding is the way this human-ready drug actually ... that are non-cancerous," said Mick Bhatia, the principal investigator ...
... WEDNESDAY, May 23 (HealthDay News) -- The risk of sudden ... more slowly through the lower chambers of the heart, a ... and cause it to pump blood through its four chambers. ... measured using an electrocardiogram (ECG). The waves traveling through the ...
Cached Medicine News:Health News:The cells' petrol pump is finally identified 2Health News:Cyber exercise partners help you go the distance 2Health News:McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones 2Health News:Study Spots Early Warning Signal for Sudden Cardiac Death 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: